INSIGHTS-JOURNAL OF
HEALTH AND REHABILITATION

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

The Impact of Omega-3 Fatty Acid Supplementation on Cognitive Function in the Elderly: A Randomized Controlled Trial

Original Article

Muhammad Fiaz[1], Hafiz Muhammad Bilal Hanif[2], Sehar Shaheen[3]*

Authors Affiliation
[1,3] Superior University, Lahore Pakistan.
https://orcid.org/0009-0000-3863-8307
https://orcid.org/0009-0009-4454-6412
[2]University of Central Lancashire, UK.
https://orcid.org/0009-0003-1665-210X

Corresponding Author*
Muhammad Fiaz
muhammadfiazctn2@gmail.com
Superior University, Lahore Pakistan
Conflict of Interest:
None

Grant Support & Financial Support:
None

Date Submitted: *12-12-2023.*

Date Published: *31-12-2023.*

Volume 1 Issue 2, 2023

Abstract

Background: Cognitive decline in the elderly is a pressing health concern, and omega-3 fatty acids have been hypothesized to mitigate this decline. Given their known benefits for brain health, including their role in neuronal structure and function, studying their potential impact on cognitive functions in elderly populations is critical.

Objective: The study aimed to evaluate the effect of omega-3 fatty acid supplementation on cognitive function as measured by standardized cognitive tests in an elderly cohort over a period of six months.

Methods: This randomized controlled trial involved 184 elderly participants, divided evenly into two groups. One group received omega-3 fatty acid supplements, while the other received a placebo. Cognitive function was assessed at baseline and after six months using the Mini-Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). The study lacked a longer follow-up period, which could be addressed in future studies to assess the long-term effects of omega-3 supplementation on cognitive decline.

Results: At six months, the omega-3 supplementation group showed a statistically significant improvement in MMSE scores, from a baseline mean of 28 to 29 ($p=0.045$), and a decrease in ADAS-Cog scores from 12 to 10 ($p=0.033$). Conversely, the placebo group exhibited a decline in MMSE scores from 27 to 26 and an increase in ADAS-Cog scores from 14 to 15.

Conclusion: Omega-3 fatty acid supplementation was associated with an improvement in cognitive performance in the elderly, suggesting its potential as a therapeutic option to mitigate age-related cognitive decline. However, further research involving larger samples and extended follow-up periods is necessary to consolidate these findings.

Keywords: ADAS-Cog, Aging, Cognitive decline, Elderly, MMSE, Omega-3, Placebo, Randomized controlled trial, Supplementation.

INTRODUCTION

In the ever-evolving landscape of medical research, the potential cognitive benefits of omega-3 fatty acids in the elderly have drawn significant attention (1). These long-chain polyunsaturated fatty acids, primarily found in oily fish, have been the subject of numerous studies aiming to unravel their efficacy in combating the cognitive decline associated with aging (2). Their critical role in brain health is underscored by their abundance in the neuronal membranes, where they influence neurogenesis, neuroplasticity, and neuroinflammation (3). The human body does not efficiently synthesize these essential nutrients, making dietary intake crucial. However, the complexity of the human diet and the variability in omega-3 absorption pose significant challenges in consistently delivering these nutrients in efficacious dosages through diet alone (4). This limitation often leads researchers to explore the impacts of supplementation in controlled clinical settings, which offer more precise measurements of omega-3's effects on cognitive outcomes (5).

Critically, while a plethora of studies underscores the potential of omega-3 fatty acids to enhance memory and executive functions, the results are not uniformly positive, presenting a nuanced landscape of benefits and limitations (6). For instance, while some randomized controlled trials report significant improvements in aspects of cognitive function, such as memory recall and executive processing, others fail to replicate these findings, suggesting a complex interaction between omega-3 fatty acids and individual biological differences (7). The variability in outcomes can be attributed to several factors, including genetic predispositions, baseline nutrient levels, and the

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

presence of other dietary or lifestyle interventions (8). This highlights the need for personalized nutrition approaches in future research endeavors (9).

Moreover, the debate surrounding omega-3 supplementation often centers on the optimal dosage and the relative proportions of its primary components—eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (10). Studies suggest that the cognitive benefits of omega-3s might be dose-dependent, with higher doses potentially required to achieve measurable impacts on brain health (11). However, this introduces concerns about the long-term safety and cost-effectiveness of high-dose omega-3 supplementation, especially in populations with pre-existing health conditions or those taking other medications (12).

In addition to dosage debates, the source of omega-3s—whether from natural fish oil or algae-derived supplements—also plays a critical role in their bioavailability and effectiveness (13). Algae-based supplements, for instance, offer a vegetarian alternative to fish oil, which is important for those with dietary restrictions but may differ in their EPA and DHA content (14). Each source comes with its ecological and economic implications, further complicating the recommendations for omega-3 supplementation (15).

This discourse enriches the ongoing dialogue within the medical and scientific communities, emphasizing the importance of well-designed clinical trials to elucidate the mechanisms through which omega-3 fatty acids influence cognitive health. As research continues to advance, it is crucial to integrate findings from a broad spectrum of studies to form comprehensive guidelines that can be applied in clinical and everyday settings. Such efforts will ensure that the potential cognitive health benefits of omega-3 fatty acids can be maximally harnessed to improve the quality of life among the elderly, a rapidly growing segment of the global population. The quest to optimize cognitive aging is not only a matter of scientific interest but also a pressing public health priority, reflecting the broader goals of enhancing lifelong health and well-being.

MATERIAL AND METHODS

In the study, 184 elderly participants were randomly assigned into two distinct groups, each comprising 92 individuals. The first group received daily supplementation of omega-3 fatty acids, while the second group was given a placebo. Both supplements were administered in identically appearing capsules to maintain blinding of both participants and researchers involved in the daily administration and subsequent evaluation. The dosage for the omega-3 fatty acids group was set at 1 gram of combined eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with a ratio of 2:1 in favor of EPA, reflective of concentrations found in high-quality fish oil supplements. The placebo group received capsules filled with olive oil, chosen for its neutral effects on cognitive health.

The duration of the intervention spanned six months, with follow-ups conducted at the end of every month. Cognitive function was assessed at baseline and at the conclusion of the study using standardized neuropsychological tests, including the Mini-Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). These assessments aimed to measure changes in memory, executive function, attention, and language skills.

Blood samples were collected from all participants at the beginning and end of the study to measure baseline and post-intervention levels of omega-3 fatty acids in plasma, which served as a biomarker for adherence to the supplementation regimen. The fatty acid composition of the participants' plasma was analyzed using gas chromatography-mass spectrometry, a reliable method for detecting precise fatty acid concentrations.

Statistical analyses were performed using the intention-to-treat principle. Changes in cognitive scores were analyzed using repeated measures ANOVA to compare the effects of omega-3 supplementation against the placebo across the study period. Covariates such as age, sex, baseline cognitive function, and dietary habits were controlled to minimize confounding variables. Additionally, subgroup analyses were conducted to explore the differential effects of omega-3 supplementation on participants with varying levels of baseline cognitive function.

The study ensured that all procedures followed were in accordance with ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. The trial was registered in a publicly accessible database prior to participant enrollment.

RESULTS

The histogram displays the age distribution of participants in two groups, with ages ranging from 60 to 85 years. Group 1 (blue) has a mean age of 70.00 years with a standard deviation (SD) of 5.00, and Group 2 (orange) has a mean age of 72.02 years with an SD of 5.00. The overlapping bars indicate a similar age range across both groups.

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

Table 1: measures of MMSE and ADAS-Cog scores for both groups

Group	MMSE Baseline	MMSE 6 Months	ADAS-Cog Baseline	ADAS-Cog 6 Months	MMSE p-value	ADAS-Cog p-value
Group 1	28	29	12	10	0.045	0.033
Group 2	27	26	14	15	0.045	0.033

The table presents cognitive assessment outcomes for two groups of elderly participants over a 6-month period, using MMSE and ADAS-Cog scores as indicators. Group 1, which received omega-3 supplementation, demonstrated cognitive improvement; their MMSE scores increased from 28 to 29, while their ADAS-Cog scores decreased from 12 to 10, suggesting enhanced cognitive function. In contrast, Group 2, receiving a placebo, experienced a decline in cognitive performance; their MMSE scores decreased from 27 to 26, and ADAS-Cog scores increased from 14 to 15, indicating cognitive deterioration. The statistical significance of these changes is confirmed by p-values of 0.045 for MMSE and 0.033 for ADAS-Cog, substantiating the superior outcomes in Group 1.



DISCUSSION

The study investigated the cognitive effects of omega-3 fatty acid supplementation compared to a placebo in elderly participants over a six-month period (16). Initial findings from the MMSE and ADAS-Cog scores illustrated that Group 1, which received omega-3 supplementation, demonstrated improvement in cognitive functions. In contrast, Group 2, which received a placebo, showed deterioration in these same cognitive metrics. This divergence in outcomes underscores the potential of omega-3 fatty acids to bolster cognitive health against age-related decline (17).

However, the results should be interpreted within the context of the study's limitations. The duration of the trial was relatively short to definitively ascertain the long-term effects of omega-3 on cognitive function. Additionally, while the sample size was adequate to detect statistical differences, a larger cohort might have provided a more robust analysis of omega-3's effects across various subgroups and could help in understanding individual variability in response to supplementation (18).

Moreover, the study's reliance on MMSE and ADAS-Cog scores as the sole measures of cognitive function could be seen as a constraint. While these tools are widely recognized and respected, they do not encompass all aspects of cognitive health. Future studies might benefit from incorporating a broader array of cognitive tests to capture more comprehensive data on cognitive function (19).

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

The debate around the efficacy of omega-3 fatty acids in cognitive enhancement is ongoing, and this study contributes to the dialogue by suggesting a potential beneficial role of these fatty acids in maintaining cognitive function in the elderly. Yet, it is crucial to approach these findings with caution given the study's limitations and the variability of dietary supplement effects among individuals (20).

CONCLUSION

The findings from this study suggest that omega-3 fatty acid supplementation may have a protective effect on cognitive decline in the elderly. This aligns with previous research highlighting the nutritional benefits of omega-3 fatty acids. However, further long-term studies with larger, more diverse populations are needed to fully determine the role of omega-3 in cognitive health and to develop tailored dietary recommendations for aging populations.

REFERENCES

1. Avallone R, Vitale G, Bertolotti MJIjoms. Omega-3 fatty acids and neurodegenerative diseases: new evidence in clinical trials. 2019;20(17):4256.

2. Denis I, Potier B, Vancassel S, Heberden C, Lavialle MJArr. Omega-3 fatty acids and brain resistance to ageing and stress: body of evidence and possible mechanisms. 2013;12(2):579-94.

3. Luchtman DW, Song CJN. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. 2013;64:550-65.

4. Nadjar A, Leyrolle Q, Joffre C, Layé S. Antiinflammatory properties of dietary n-3 polyunsaturated fatty acids protect against cognitive decline in aging and neurodegenerative diseases. Role of the Mediterranean Diet in the Brain and Neurodegenerative Diseases: Elsevier; 2018. p. 367-84.

5. Phillips CJNp. Lifestyle modulators of neuroplasticity: how physical activity, mental engagement, and diet promote cognitive health during aging. 2017;2017.

6. Castellanos-Perilla N, Borda MG, Aarsland D, Barreto GEJERoN. An analysis of omega-3 clinical trials and a call for personalized supplementation for dementia prevention. 2023:1-12.

7. Mora I, Arola L, Caimari A, Escoté X, Puiggròs FJIjoms. Structured long-chain omega-3 fatty acids for improvement of cognitive function during aging. 2022;23(7):3472.

8. Scarmeas N, Anastasiou CA, Yannakoulia MJTLN. Nutrition and prevention of cognitive impairment. 2018;17(11):1006-15.

9. Saleh RN, Minihane AMJPotNS. Fish, n-3 fatty acids, cognition and dementia risk: not just a fishy tale. 2022;81(1):27-40.

10. Leshno M, Goldbourt U, Pinchuk I, Lichtenberg DJIJoFS, Nutrition. The cardiovascular benefits of indiscriminate supplementation of omega-3 fatty acids; meta-analysis and decision-making approach. 2018;69(5):549-56.

11. Saini RK, Keum Y-SJLs. Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance—A review. 2018;203:255-67.

12. Baker EJJCOiCN, Care M. Alternative sources of bioactive omega-3 fatty acids: what are the options? 2023;27(2):106-15.

13. Liu Y, Ren X, Fan C, Wu W, Zhang W, Wang YJF. Health benefits, food applications, and sustainability of microalgae-derived N-3 PUFA. 2022;11(13):1883.

14. Kusmayadi A, Leong YK, Yen H-W, Huang C-Y, Chang J-SJC. Microalgae as sustainable food and feed sources for animals and humans–biotechnological and environmental aspects. 2021;271:129800.

15. Koyande AK, Chew KW, Rambabu K, Tao Y, Chu D-T, Show P-LJFS, et al. Microalgae: A potential alternative to health supplementation for humans. 2019;8(1):16-24.

16. Wood AH, Chappell HF, Zulyniak MAJEJoN. Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer's disease. 2022:1-16.

17. D'Cunha NM, Georgousopoulou EN, Dadigamuwage L, Kellett J, Panagiotakos DB, Thomas J, et al. Effect of long-term nutraceutical and dietary supplement use on cognition in the elderly: a 10-year systematic review of randomised controlled trials. 2018;119(3):280-98.

18. Leckie RL, Lehman DE, Gianaros PJ, Erickson KI, Sereika SM, Kuan DC, et al. The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: A randomized clinical trial. 2020;50(14):2425-34.

19. Harrison JE, Rentz D, Brashear H, Arrighi H, Ropacki M, Liu EJTJoPoAsD. Psychometric evaluation of the neuropsychological test battery in individuals with normal cognition, mild cognitive impairment, or mild to moderate Alzheimer's disease: Results from a longitudinal study. 2018;5:236-44.

20. Alex A, Abbott KA, McEvoy M, Schofield PW, Garg MLJNr. Long-chain omega-3 polyunsaturated fatty acids and cognitive decline in non-demented adults: a systematic review and meta-analysis. 2020;78(7):563-78.

